Your session is about to expire
← Back to Search
Zinc Oxide vs. Petrolatum for Scarring
Study Summary
This trial is testing whether zinc oxide or petrolatum is more effective in healing scars. Patients will apply either zinc oxide or petrolatum to one half of their scar daily for a month and keep a log of their activities. They will be seen at 1 week, 4 weeks, 8 weeks, and 6 months post-operatively for photographic scar assessment and to complete the patient portion of the Patient and Observer Scar Assessment Scale. Trained observers will score the observer portion of the scale.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there existing surveys that attest to the efficacy of this treatment?
"At this time, 8 studies on the efficacy of this treatment are underway. Of these, 0 have progressed to Phase 3 clinical trials. Most research centres are situated in Boston but there are 11 locations overall hosting investigations for this medication."
Are there any available openings for participants in this experiment?
"Affirmative. According to clinicaltrials.gov, the trial is currently accepting new participants and was initially posted on September 1st 2021. The study requires 30 enrollees from a single medical centre as of April 14th 2022."
What is the conventional application of this remedy?
"Generally, this medication is applied to sunburns. However, additional applications may involve treating dermabrasion and chafing of the skin."
How many individuals are receiving the benefits of this trial's protocol?
"Affirmative. The information furnished on clinicaltrials.gov confirms that this research, which commenced in September 2021, is currently seeking participants. 30 individuals are being admitted at a single site for the duration of the trial."
Share this study with friends
Copy Link
Messenger